Akdis Mübeccel
Swiss Institute of Allergy and Asthma Research (SIAF) Davos, Obere Strasse 22, CH-7270 Davos Platz, Switzerland ; Christine Kühne - Center for Allergy Research and Education, Davos Platz, Switzerland.
World Allergy Organ J. 2014 Sep 24;7(1):23. doi: 10.1186/1939-4551-7-23. eCollection 2014.
Allergen-specific immunotherapy (SIT) represents the only curative and specific way for the treatment of allergic diseases, which have reached a pandemic dimension in industrial countries affecting up to 20-30% of the population. Although applied for 100 years to cure allergy, SIT still faces several problems related to side effects and limited efficacy. Currently, allergen-SIT is performed with vaccines based on allergen extracts that can cause severe, often life threatening, anaphylactic reactions as well as new IgE sensitization to other allergens present in the extract. Low patient adherence and high costs due to long duration (3 to 5 years) of treatment have been commonly reported. Several strategies have been developed to tackle these issues and it became possible to produce recombinant allergen-SIT vaccines with reduced allergenic activity.
变应原特异性免疫疗法（SIT）是治疗过敏性疾病的唯一具有治愈性且特异性的方法，在工业化国家，过敏性疾病已达到大流行程度，影响高达20%-30%的人口。尽管SIT已应用于治疗过敏症长达100年，但仍面临一些与副作用和疗效有限相关的问题。目前，变应原-SIT是使用基于变应原提取物的疫苗进行的，这些提取物可能会引发严重的、常常危及生命的过敏反应，以及对提取物中存在的其他变应原产生新的IgE致敏。普遍报道称，患者依从性低以及由于治疗时间长（3至5年）导致成本高昂。已经开发了几种策略来解决这些问题，并且有可能生产出变应原活性降低的重组变应原-SIT疫苗。
